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Acute myeloid leukemia is a malignant disease of immaturemyeloid cells. Despite significant therapeutic effects of differ-entiation-inducing agents in some acute myeloid leukemia sub-
types, the disease remains incurable in a large fraction of patients.
Here we show that SK053, a thioredoxin inhibitor, induces differenti-
ation and cell death of acute myeloid leukemia cells. Considering that
thioredoxin knock-down with short hairpin RNA failed to exert
antiproliferative effects in one of the acute myeloid leukemia cell
lines, we used a biotin affinity probe-labeling approach to identify
potential molecular targets for the effects of SK053. Mass spectrome-
try of proteins precipitated from acute myeloid leukemia cells incubat-
ed with biotinylated SK053 used as a bait revealed protein disulfide
isomerase as a potential binding partner for the compound.
Biochemical, enzymatic and functional assays using fluorescence life-
time imaging confirmed that SK053 binds to and inhibits the activity
of protein disulfide isomerase. Protein disulfide isomerase knock-
down with short hairpin RNA was associated with inhibition of cell
growth, increased CCAAT enhancer-binding protein a levels, and
induction of differentiation of HL-60 cells. Molecular dynamics simu-
lation followed by the covalent docking indicated that SK053 binds to
the fourth thioredoxin-like domain of protein disulfide isomerase.
Differentiation of myeloid precursor cells requires the activity of
CCAAT enhancer-binding protein a, the function of which is
impaired in acute myeloid leukemia cells through various mecha-
nisms, including translational block by protein disulfide isomerase.
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SK053 increased the levels of CCAAT enhancer-binding protein a and upregulated mRNA levels for
differentiation-associated genes. Finally, SK053 decreased the survival of blasts and increased the per-
centage of cells expressing the maturation-associated CD11b marker in primary cells isolated from
bone marrow or peripheral blood of patients with acute myeloid leukemia. Collectively, these results
provide a proof-of-concept that protein disulfide isomerase inhibition has potential as a therapeutic
strategy for the treatment of acute myeloid leukemia and for the development of small-molecule
inhibitors of protein disulfide isomerase.
Introduction
Acute myeloid leukemia (AML), the most prevalent
acute leukemia among adults, is a malignancy of
myeloid lineage cells characterized by the inhibition of
cell differentiation leading to accumulation of abnormal
white blood cells.1 The use of differentiation-inducing
agents, such as all-trans retinoic acid and arsenic triox-
ide, for the treatment of acute promyelocytic leukemia
has brought remarkable therapeutic effects.2,3 However,
not all patients with acute promyelocytic leukemia ben-
efit from differentiation treatment and there has been
no such significant progress in the treatment of other
types of AML.4 The development of new therapeutic
agents exerting anti-leukemic effects by targeting
unique cellular mechanisms of differentiation is still,
therefore, a pressing need of clinical importance.5 It is
particularly desirable to develop differentiation-promot-
ing compounds that induce terminal differentiation of
leukemic cells leading to cell cycle arrest followed by
cell death, and obviate overt cytotoxicity.
A critical transcription factor involved in the develop-
ment and differentiation of myeloid lineage cells is
CCAAT enhancer-binding protein a (C/EBPa). In
C/EBPa-deficient mice granulocyte differentiation is
blocked,6 and C/EBPa expression in bipotential
myeloid progenitors is sufficient to induce granulocytic
development.7 Dysregulation of C/EBPa activity is fre-
quently observed in AML patients. Lack of, aberrant or
suboptimal C/EBPa activity can result from genomic
mutations in the CEBPA gene,8 transcriptional suppres-
sion originating from promoter hypermethylation, or
functional inactivation by phosphorylation.9 A transla-
tional block that occurs in cells experiencing endoplas-
mic reticulum stress has also been reported as a mech-
anism leading to C/EBPa downregulation at the mRNA
level.10 Various mechanisms such as loss of Ca2+ home-
ostasis, inhibition of disulfide bond formation, oxida-
tive stress, or hypoxia, lead to endoplasmic reticulum
stress, which triggers the unfolded protein response.
The role of the unfolded protein response is to restore
protein homeostasis and normal endoplasmic reticulum
function. Accordingly, this response has been reported
to be upregulated in a significant percentage of patients
with AML and to be associated with a more favorable
course of the disease.10
We have previously developed SK053, a pep-
tidomimetic inhibitor of thioredoxin that exerts cytosta-
tic/cytotoxic effects and endoplasmic reticulum stress-
mediated apoptosis in tumor cells.11 Conspicuously, we
have observed that AML cells incubated with SK053
undergo growth arrest followed by differentiation into
more mature myeloid stages and cell death. We, there-
fore, employed RNA sequencing and a biotin affinity
probe-labeling approach to identify the molecular
mechanism of the differentiation-promoting effects of
SK053, revealing protein disulfide isomerase (PDI) as a
druggable target for AML treatment.
Methods
A detailed description of the methods used can be found in
the Online Supplementary Data file.
Culture conditions for the acute myeloid leukemia cell
lines
NB4, MOLM14, HS-5 and HL-60 cells were cultured in RPMI
1640 (Sigma-Aldrich) supplemented with 10% heat-inactivated
fetal bovine serum (Hyclone), 100 mg/mL streptomycin and 100
U/mL penicillin (P/S, Sigma-Aldrich). KG1 cells were cultured in
IMDM (Gibco) supplemented with 20% heat-inactivated fetal
bovine serum (Hyclone) and P/S. HeLa cells were cultured in
DMEM (Gibco) supplemented with 10% heat-inactivated fetal
bovine serum (Hyclone) and P/S. All cells were cultured at 37°C
in a fully humidified atmosphere of 5% CO2. 
Acute myeloid leukemia cell differentiation assays
Myeloid differentiation was assessed by staining cytospun
cells with May-Grünwald-Giemsa as well as in flow cytometry
by examining the surface expression of CD11b. A conventional
semi-quantitative microscopic nitroblue tetrazolium (NBT;
Sigma-Aldrich) assay was used to determine the production of
superoxide anion upon stimulation with phorbol myristate
acetate in differentiated AML cells. A modified quantitative
NBT assay was established and implemented by dissolving the
blue formazan particles from equal cell numbers in sodium
hydroxide, followed by measurement of absorbance at 620 nm
using an ASYS UVM 340 microplate reader (Biochrom,
Cambridge, UK). 
RNA extraction and quantitative real-time polymerase
chain reaction
Total RNA was extracted from HL-60 cells using an RNA
purification kit (EurX) and relative gene expression was quanti-
fied using a LightCycler II 480 Real-Time PCR System (Roche,
Basel, Switzerland), LightCycler Probes Master and hydrolysis
probes [Universal Probe Library (UPL), Roche] according to the
manufacturer's recommendations. 
Western blot
HL-60 cells were washed twice with ice-cold phosphate-
buffered saline, lysed in RIPA buffer (50 mmol/L Tris base, 150
mmol/L NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1
mmol/L EDTA) or cytoplasmic/nuclear fractions of proteins
were extracted using an NE-PER Kit (Pierce). Immunoblotting
was done via standard procedures using the antibodies accord-
ing to the manufacturer’s instructions. 
Isolation of primary acute myeloid leukemia blasts and
evaluation of the anti-leukemic effects of SK053 
The study was approved by the Institutional Review Board of
the Medical University of Lublin (approval n. KE-0254/71/2010)
and the Medical University of Warsaw (approval n. KB
182/2011) and was conducted according to the Declaration of
Helsinki. Each patient signed written informed consent to the
procedures. Leukemic cells were obtained from the bone mar-
row of patients with AML and isolated by 1.077 g/mL
Histopaque (Sigma-Aldrich) density gradient centrifugation.
Cells were seeded in IMDM culture medium, supplemented
with 10% heat-inactivated fetal bovine serum at a density
5×105 cells/mL and incubated for 72 h with SK053. Cytotoxic
effects, growth and differentiation upon incubation with SK053
were evaluated with methods described above. 7-AAD staining
was used to discriminate dead cells. Additionally, anti-CD33
antibody (BD Biosciences, cat. n. 551378) was used to identify
myeloid cells among all peripheral blood mononuclear cells.
The patients’ basic characteristics are shown in Online
Supplementary Table S11.
Statistical analysis
Data were analyzed using Microsoft Excel 2010 and
GraphPad Prism 6.0 for Windows (GraphPad Software Inc., La
Jolla, CA, USA) software. The results were analyzed for signif-
icance using a two-tailed Student t-test or one-way ANOVA
with a Dunnett post-hoc test. Statistical significance was defined
as P values <0.05.
Results
SK053 induces differentiation of acute myeloid
leukemia cells
HL-60 acute promyelocytic leukemia cells were incu-
bated for 24 to 120 h with increasing concentrations of
SK053 and cell growth as well as cytotoxic effects were
determined by counting viable cells and flow cytometry.
SK053 inhibited cell growth in a time- and concentra-
tion-dependent manner (Figure 1A). We observed similar
cytotoxic effects of SK053 against HL-60 cells grown in
cell culture medium alone or on the top of bone marrow
stromal cells (HS5) mimicking the interaction between
AML blasts and the bone marrow niche (Figure 1B). HL-
60 cells incubated with SK053 also showed features of
more mature myelopoietic stages with a decreased
nucleus/cytoplasm ratio and a greater reduction of NBT
(Figure 1C), corresponding to NADPH oxidase activity.
An NBT reduction assay (Figure 1D) as well as increased
surface levels of CD11b measured in flow cytometry
(Figure 1E) confirmed the differentiation-promoting
effects of SK053. Quantitative real-time polymerase
chain reaction analysis revealed that incubation of HL-60
cells with SK053 resulted in increased levels of tran-
scripts for differentiation-associated genes, such as dif-
ferentiation-driving transcription factors (CEBPB,
CEBPE), early markers of neutrophil differentiation
(HK3) and genes expressed by mature granulocytes
(CSF3R encoding G-CSFR, CSF2R encoding GM-CSFR,
ELANE and MPO) (Figure 1F). Cytostatic/cytotoxic and
differentiation-promoting effects of SK053 were also
observed in NB4, another acute promyelocytic leukemia
cell line, as well as in non-acute promyelocytic leukemia
AML cell lines, such as MOLM14 and KG1 (Online
Supplementary Figure S1).
SK053 induces gene expression profile associated
with stress response and differentiation
To get further insight into the mechanisms of SK053
activity in AML cells, we sequenced and analyzed tran-
scriptomes of controls and SK053-treated HL-60 cells
using next-generation sequencing. Analysis of transcrip-
tomes of controls and HL-60 cells incubated with SK053
for 48 h (Online Supplementary Figure S2) revealed differen-
tial expression of genes (Online Supplementary Figure S3A,
Online Supplementary Table S1) that, in gene ontology
analysis, clustered into two major groups: (i) biological
processes (Online Supplementary Figure S3B, Online
Supplementary Table S2) involving the stress response (e.g.
genes encoding calreticulin or proteasome subunits), reg-
ulation of apoptosis  (e.g. genes encoding Bcl-2-related
protein, CFLAR or TNFRSF10B) and myeloid cell differen-
tiation (CBFB, JAK2 or PIR) and (ii) molecule function
(Online Supplementary Figure S3C, Online Supplementary
Table S3) associated with changes in oxidoreductases
activity [e.g. NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, ATP synthase or cytochrome c].
Furthermore, a 5-day incubation of HL-60 cells with
SK053 induced the expression of genes regulating
myeloid cell differentiation (JUN, CSF1, ID2) and cell pro-
liferation (BCL6, PNMT) (Online Supplementary Figure
S4A-C, Online Supplementary Tables S4-S6).
Immunoblotting of the lysates of HL-60 cells confirmed
the results of the next-generation sequencing analysis
showing that SK053 induces endoplasmic reticulum
stress and the unfolded protein response (Online
Supplementary Figure S5).
SK053 binds to and inhibits protein disulfide
isomerase
We then used lentiviral particles encoding short hairpin
RNA (shRNA) to target thioredoxin in HL-60 cells.
Intriguingly, thioredoxin knock-down with shRNA failed
to inhibit the growth of HL-60 cells (Online Supplementary
Figure S6A). Subsequently, we used two other shRNA
sequences targeting thioredoxin (Online Supplementary
Figure S6B) and assessed the effects of thioredoxin knock-
down in HL-60 and MOLM14 cells. While both hairpins
effectively suppressed the growth of MOLM14 cells, only
one shRNA slightly inhibited and the other had no effect
on the growth of HL-60 cells (Online Supplementary Figure
S6C,D). These observations indicate that inhibition of
thioredoxin might not be responsible for the differentia-
tion-inducing effects of SK053 in HL-60 cells. Therefore,
using a biotin affinity probe-labeling approach followed
by mass spectrometry, we sought to identify other poten-
tial intracellular SK053 targets in these cells. Incubation of
HL-60 cells for 4 h with SK-BIO, an active, biotinylated
SK053 analog (see Online Supplementary Figure S8 for the
general structures of compound used herein), followed by
pulldown with avidin-coated beads and sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
revealed a prominent band of ~50-70 kDa molecular
weight in silver-stained gels (Figure 2A). An inactive,
biotinylated analog of SK053 that lacks the electrophilic
double bond (referred to as SK-IN, Online Supplementary
Figure S8) failed to precipitate any protein. The ~50-70
kDa protein was identified in mass spectrometry to be a
protein disulfide isomerase (PDI), a product of the P4HB
gene (Online Supplementary Figure S9A-D, Online
Supplementary Table S7). SDS-PAGE followed by the
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Figure 1. SK053 induces differen-
tiation of AML cells. (A) HL-60
cells were incubated with various
concentrations of SK053 for up to
5 days. Each day the number of
dead cells was evaluated with try-
pan blue exclusion (mean ± SD
from 6 experiments). (B) Co-cul-
ture of HL-60 cells with universal
bone marrow stromal cells (HS5)
did not impair SK053 cytotoxicity.
HL-60 cells were seeded in a tran-
swell system on top of HS5 cells
and incubated with SK053 for 72
h. Next, HL-60 cells were analyzed
for viability using propidium iodide
(PI) staining in flow cytometry
(data are shown as mean percent-
ages of PI-positive cells ± SD from
3 experiments); *P<0.05 in one-
way ANOVA with the Dunnett post-
hoc test. (C) May-Grünwald-
Giemsa (MGG) staining (upper
panel) and nitro-blue tetrazolium
(NBT) (lower panel) in HL-60 cells
incubated with SK053 for 120 h.
All-trans retinoic acid (ATRA)
served as a positive control. (D)
Semi-quantitative colorimetric
NBT reduction assay in HL-60 cells
incubated for 5 days with 10 mM
SK053 (data are shown as mean
increases, in %, over controls ± SD
for 3 experiments); *P<0.05 in
one-way ANOVA with the Dunnett
post-hoc test. (E) Mean percent-
age ± SD of HL-60 cells expressing
CD11b myeloid marker was deter-
mined in flow cytometry in 3
experiments; *P<0.05 in one-way
ANOVA with the Dunnett post hoc
test. (F) Real-time quantitative
polymerase chain reaction analy-
sis of HL-60 cells incubated for 5
days with 10 mM SK053; results
are presented as mean target-to-
reference ratio ± SD of three
experiments; *P<0.05 vs. con-
trols, two-tailed Student t test,
#P<0.05 vs. controls, one-tailed
Student t test.
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detection of biotin revealed covalent binding of SK-BIO
to recombinant human (rhu) PDI (Figure 2B). Oxidation
of rhuPDI, which decreases the number of sulfhydryl
groups, reduced binding of SK-BIO to PDI indicating a
thiol-dependent interaction (Figure 2C). Moreover, in a
competition assay, pre-incubation of rhuPDI with SK053
prevented binding of SK-BIO, indicating the same binding
site for both compounds (Figure 2B).
Immunoprecipitation of PDI and thioredoxin from the
lysates of HL-60 cells cultured with SK-BIO revealed the
presence of biotinylated PDI but not thioredoxin (Figure
2D), indicating that in HL-60 cells PDI is a preferential tar-
get for the compound. Further mass spectrometry
revealed that SK053 binds to the catalytic cysteines local-
ized in the fourth thioredoxin-like domain of PDI (Online
Supplementary Figure S9E). Furthermore, the molecular
dynamics simulation followed by covalent docking of
SK053 to the fourth thioredoxin-like domain of human
PDI (pdb|4ekz) indicated that the binding of the truncated
form of SK053 (a molecule without the leaving group,
Online Supplementary Figure S8D) is equally likely to occur
by forming a covalent bond with either sulfur from
Cys397 or Cys400 (Online Supplementary Figure S10,
Online Supplementary Movie 1). Next, we sought to deter-
mine whether binding of SK053 translates into inhibition
of PDI activity. A turbidimetric assay of PDI-mediated
insulin reduction revealed that SK053 efficiently blocks
the enzymatic activity of rhuPDI with an IC50 value of
9.98 mM (Figure 3A,B). To further investigate whether
SK053 can inhibit PDI activity in cells, we transfected
HeLa cervical cancer cells with a plasmid encoding an
endoplasmic reticulum-tuned fluorescent redox-respon-
sive probe (roGFPiE)12 and measured the response of this
probe using fluorescence lifetime imaging in a time-corre-
lated single-photon counting mode. The fluorescent life-
time of the probe declined in SK053-treated HeLa cells,
reflecting the reductive shift in the dithiol-disulfide
steady state and indicating SK053-mediated inhibition of
PDI activity in the endoplasmic reticulum of living cells
(Figure 3C). 
Inhibition of protein disulfide isomerase increases
C/EBPa levels and inhibits the growth of acute
myeloid leukemia cells
Recently, it was shown that PDI interacts with the stem
loop region of mRNA for C/EBPa thereby blocking its
translation.13 Considering that C/EBPa is a crucial tran-
scription factor driving myeloid cells differentiation14,15 we
investigated the effects of SK053 on C/EBPa levels in AML
cells. Incubation of HL-60 cells with SK053 increased the
nuclear levels of the 42 kDa C/EBPa isoform (Figure 4A)
and induced CEBPA mRNA expression (Figure 4C).
Additionally, the oncogenic p30 kDa C/EBPa levels were
strongly suppressed in cells incubated with SK053 (Figure
4B). Accordingly, SK053 decreased the levels of SOX4
mRNA (Figure 1G), a direct target of C/EBPa, the expres-
Protein disulfide isomerase as a target in leukemia
haematologica | 2018; 103(11) 1847
Figure 2. SK053 binds to protein disulfide isomerase. (A) HL-60 cells were incubated with 100 mM SK-BIO and lysed. Proteins binding SK-BIO were precipitated with
avidin-coated beads and eluted with buffers E1 and E2 as described in the Methods section. Next, the samples were separated by SDS-PAGE. A band obtained with
buffer E1 (black rectangle) was excised from silver-stained gel and analyzed by mass spectrometry. An inactive biotinylated SK053 analog (SK-IN) was used as a neg-
ative control. A representative result of a series of experiments is presented. (B) Recombinant human (rhu) PDI was incubated with a 10× molar excess of SK-BIO
for 10-120 min at 37°C (left) or preincubated for 1 h with a 10× molar excess of SK053 followed by 1 h incubation with a 10× molar excess of SK-BIO (right). Next,
proteins were separated by SDS-PAGE followed by western blotting (WB) using anti-biotin monoclonal antibody. Membranes stained with Ponceau red served as load-
ing controls. A representative result of a series of experiments is presented. (C) Reduced (red) and oxidized (ox) rhuPDI were incubated with SK-BIO followed by
immunoblotting for biotin. Gels stained with Coomasie blue served as loading controls. SK-IN was used as a negative control. A representative result of a series of
experiments is presented. (D) The lysates of HL-60 cells were incubated with SK-BIO followed by biotin immunoprecipitation and western blotting. Biotin detection in
total cell lysates (input) was used as a loading control. Lysate incubated with protein G agarose beads in the absence of antibodies was used as a negative control
(No Ab). A representative result of a series of experiments is presented. IP: immunoprecipitation; TXN: thioredoxin.
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sion of which has been shown to correlate inversely with
C/EBPa activity, increased self-renewal of leukemic cells
as well as a block in blast differentiation.16 shRNA-mediat-
ed knock-down of PDI (P4HB) expression significantly
suppressed the proliferation of HL-60 cells (Figure 4D,E).
Lentiviral transduction of HL-60, MOLM14 and KG1 cells
with another shRNA sequence confirmed that PDI knock-
down is associated with significant growth suppression
(Figure 4F,G) and upregulates C/EBPa protein (Online
Supplementary Figure S7A). PDI knock-down also increased
the percentage of CD11b+ HL-60 cells as compared with
nontargeting controls, but failed to do so in MOLM14 and
KG1 cells (Figure 4H). Unexpectedly, SK053 strongly sup-
pressed the growth and induced differentiation of HL-60
cells transduced with two independent shRNA sequences
targeting CEBPA (Online Supplementary Figure S7B-D), indi-
cating that the presence of this differentiation-associated
transcription factor is not necessary for the antileukemic
effects of SK053.
Protein disulfide isomerase inhibition targets
leukemia-initiating cells and is effective in primary
acute myeloid leukemia cells
AML is characterized by a small population of self-
renewing leukemic stem cells referred to as leukemia-ini-
tiating cells that give rise to a large population of imma-
ture leukemic blasts.17 Since leukemia-initiating cells are
intrinsically resistant to chemotherapeutics and AML fre-
quently relapses due to incomplete elimination of
leukemia-initiating cells18 we sought to investigate the
effects of SK053 on the survival of CD123+CD34+CD38-
leukemia-initiating cell-like cells within the KG1 AML
cell line. We observed a concentration-dependent
decrease in the percentage of these cells when incubated
with SK053 (Figure 5A,B). Moreover, pretreatment of
KG1 cells with SK053 decreased the clonogenic potential
of these cells in a colony formation assay in vitro (Figure
5C,D). Moreover, SK053 exerted antileukemic effects in
primary AML blasts isolated from bone marrow or
peripheral blood of AML patients. We observed a
decrease in blast survival in all samples from six patients
investigated, accompanied by an increased percentage of
cells expressing CD11b marker in five out of the six sam-
ples (Figure 6).
Discussion
In this study we demonstrate that SK053 induces differ-
entiation of AML cells. SK053 has been developed as a
thioredoxin inhibitor and was reported to induce endo-
plasmic reticulum stress and apoptosis of tumor cells.11
Thus, it was to some extent unexpected to observe that
SK053 induces cytostatic/cytotoxic effects against HL-60
cells (Figure 1A,B), while thioredoxin knock-down with
shRNA turned out to be largely ineffective in suppressing
the growth of these cells (Online Supplementary Figure
S6C). This observation prompted us to look for an addi-
tional cellular target for SK053. Using biotinylated SK053
as a bait in a biotin affinity probe-labeling approach we
observed that SK053 binds to PDI (Figure 2, Online
Supplementary Figure S9). Molecular docking confirmed
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Figure 3. SK053 inhibits enzymatic activity of protein disulfide isomerase. (A) A turbidimetric assay of recombinant human PDI-mediated insulin disulfide reduction
(mean ± SD of 6 experiments). (B) Determination of the IC50 value for SK053 with SigmaPlot software. (C) Fluorescence lifetime imaging (FLIM) of HeLa cells trans-
fected with plasmid encoding an endoplasmic reticulum-tuned fluorescent redox-responsive probe (roGFPiE) tracking the activity of the PDI in cells; 100 mM dithio-
threitol (DTT), a reducing agent, was used as a positive control. A representative result of a series of experiments is presented. 
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Figure 4.SK053 increases CEBPA levels in HL-60 cells and protein disulfide isomerase
knock-down impairs the growth of acute myeloid leukemia cells and induces differenti-
ation of HL-60 cells.  (A) HL-60 cells were incubated for 2 or 5 days with 10 mM SK053.
Subcellular fractions were isolated using a NE-PER kit. HDAC2 served as a loading control
for the nuclear fraction. A representative result of a series of experiments is presented. (B)
HL-60 cells were incubated for 1-120 h with 10 mM SK053, harvested, lysed and total cell
lysates were immunoblotted for 30 kDa C/EBPa. a-tubulin levels served as a loading con-
trol. A representative result of a series of experiments is presented. For (A) and (B) the con-
trols are HL-60 cells incubated with dimethylsulfoxide at the same concentration as used
for SK053-treated group, harvested on day 5. (C) Real-time quantitative polymerase chain
reaction of HL-60 cells incubated for the indicated times with 10 mM SK053; results are
presented as mean target-to-reference ratio ± SD of three experiments. (D) Western blot
showing the efficacy of PDI or thioredoxin (TXN) knock-down 5 days after transduction with
shRNA-encoding lentiviruses. PDI(a) and PDI(b) indicate two different shRNA; β-actin (βA)
served as a loading control. (E) Growth of HL-60 cells transduced with non-targeting (NTC),
TXN [TXN(a)]- or PDI [PDI(b)]-targeting shRNA lentiviral particles. Cells were counted daily
in trypan blue from day 1 until day 8. *P<0.05 vs. NTC in a two-tailed Student t-test. For
(C) and (D) the controls are non-modified HL-60 cells. (F) Western blot showing the efficacy
of PDI knock-down in AML cell lines transduced with PDI-targeting shRNA [PDI(d)]-encod-
ing lentiviruses. GAPDH served as a loading control. (G) Growth of HL-60, MOLM14 and
KG1 cells transduced with non-targeting (NTC) or PDI-targeting [PDI(d)] shRNA lentiviral
particles. Cells were counted daily in trypan blue from day 1 until day 9. *P<0.05 vs. NTC
in a two-tailed Student t-test. (H) Mean percentage ± SD of AML cells modified with non-
targeting (NTC) or PDI-targeting [PDI(d)] shRNA, expressing CD11b myeloid marker deter-
mined in flow cytometry (n=4 experiments, except for KG1: n=2), ***P<0.0001 vs. NTC,
two-tailed Student t-test; NS: not significant. 
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the feasibility of this interaction (Online Supplementary
Figure S10) and further precipitation, as well as enzymatic
and functional analyses, revealed that SK053 binds to and
inhibits the activity of human PDI (Figures 2 and 3).
PDI is the original member of a family of PDI proteins
that contain a characteristic CXXC motif, with two cys-
teine residues forming a disulfide bond that is cleaved by
oxidoreductases or by thiol-disulfide exchange. Although
all PDI family members contain a thioredoxin-like domain,
they differ considerably in size, domain composition and
enzymatic properties. PDI is involved in the formation and
isomerization of disulfide bonds between cysteine residues
of polypeptides as they fold.19 Such disulfide modifications
participate in post-translational protein control and affect
the functions of many proteins. PDI also participates in the
maintenance of cellular homeostasis by mediating oxida-
tive protein folding and acts as a chaperone.19 A number of
studies indicate that various PDI are highly expressed in
multiple cancer types as compared with matched normal
tissues and play an important role in supporting cancer
progression.19 PDI is induced in tumor cells during the
unfolded protein response and has been associated with
chemoresistance.20,21 Inhibition of PDI activity with a non-
selective inhibitor, bacitracin, enhanced apoptosis triggered
by bortezomib or fenretinide.22 Propynoic acid carbamoyl
methyl amide (PACMA31), an irreversible PDI inhibitor,
exhibited significant antitumor effects in ovarian cancer
models23 and potentiated the antitumor effects of sorafenib
in hepatocellular carcinoma.24 A structurally different PDI
inhibitor (CCF642) was shown to exert anti-myeloma
activity associated with the induction of endoplasmic retic-
ulum stress and apoptosis-inducing calcium release.25 All
these observations indicate that PDI is a potential drug tar-
get in cancer treatment. 
Remarkably, Heafliger et al. have shown that PDI binds
to the stem loop region of C/EBPa mRNA, thereby block-
ing its translation.13 Our results indicate that SK053 upreg-
ulates C/EBPa levels (Figure 4), downregulates its down-
stream effector SOX4, and induces differentiation of AML
cells (Figure 1F). However, despite C/EBPa upregulation
we have observed that SK053 still exerts potent growth-
inhibitory effects in HL-60 cells with stably suppressed
CEBPA expression induced by two different shRNA
sequences (Online Supplementary Figure S7). Thus, it seems
unlikely that PDI inhibition with SK053 directly leads to
stabilization of CEBPA mRNA. Nonetheless, PDI knock-
J. Chlebowska-Tuz et al.
1850 haematologica | 2018; 103(11)
Figure 5. SK053 decreases the percentage of KG1 leukemia-initiating cells and their clonogenic potential in vitro. (A) KG1 cells were incubated for 72 h with the
indicated concentrations of SK053, harvested and stained for flow cytometry. Representative density plots from a series of experiments are presented. (B) Mean per-
centages of CD123+ KG1 cells among CD34+ and CD38– cells ± SD (n=3 experiments) *P<0.05 vs. controls, one-way ANOVA with Dunnett post-hoc test. (C)
Representative pictures of the clonogenic assay plates on day 14 after seeding KG1 cells pretreated for 72 h with SK053. (D) Mean clone size (pixel area) ± SEM
(n=3 experiments); **P<0.0001 vs. controls, one-way ANOVA with Dunnett post-hoc test.
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Figure 6. SK053 exerts antileukemic effects and induces differentiation of primary leukemic blasts isolated from the bone marrow of patients with acute myeloid
leukemia.  (Left) Primary AML blasts isolated from six patients (numbered consecutively Pt 1 to Pt 6) were incubated with the indicated concentrations of SK053
for 72 h. Each day the number of dead cells was evaluated with trypan blue exclusion. Graphs present mean percentages of dead cells ± SD (n=6 experiments).
*P<0.05 vs. controls, one-way ANOVA with Dunnett post-hoc test. (Right) Primary AML blasts isolated from six patients were incubated with the indicated concen-
trations of SK053 for 72 h. Percentages of CD11b+ cells among live (7-AAD-) and CD33+ cells were evaluated in flow cytometry. Graphs present mean percentages
of dead cells ± SD (n=3 experiments). *P<0.05 vs. controls, one-way ANOVA with Dunnett post-hoc test.
down with shRNA (Figure 4) exerted cytostatic/cytotoxic
effects in HL-60, MOLM14 and KG1 cells and induced dif-
ferentiation of HL-60 cells. In contrast to HL-60 cells,
thioredoxin knock-down in MOLM14 and KG1 cells was
also associated with inhibition of cell growth. Thus, it
seems that both thioredoxin and PDI are involved in the
survival of these cells, and since SK053 targets both
enzymes, the antileukemic activity of this compound can
be attributed to its dual selectivity. The findings that
SK053 significantly decreases the percentage of
CD123+CD34+CD38– leukemia-initiating cells and
decreases the clonogenic potential of these cells in the
colony formation assay in vitro are particularly important.
Leukemia-initiating cells seem to have a pivotal role in the
relapse of AML and are considered to be resistant to con-
ventional chemotherapy and targeted therapies.26
Altogether, we show that SK053 targets PDI by thiol-
dependent interactions, modulates C/EBPα levels and
induces differentiation of AML cells. These observations
indicate that PDI is a druggable target for differentiation
treatment in AML.
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